SavedAdd your journal

Journals / Anadolu Üniversitesi Bilim ve Teknoloji Dergisi :C-Yaşam Bilimleri ve Biyoteknoloji / 2018 / Cilt: 7 - Sayı: 1

ATTRACTIVE APPROACHES IN siRNA DELIVERY USING POLYMER BIO-BASED CARRIER SYSTEMS

Şükrü TÜZMEN
Zülal YALINCA
Pages
74–91
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Functional characterization of genes can be determined by disruption of gene expression.
📊
Key Findings & Data:This provides powerful approach in designing novel treatment strategies.
💡
Conclusion & Impact:Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Functional characterization of genes can be determined by disruption of gene expression. This provides powerful approach in designing novel treatment strategies. RNA interference (RNAi) is a natural phenomenon that can aid in the study of post-transcriptional regulation of genes. This mechanism can be stimulated via introduction of double stranded RNA (dsRNA) in a cell. Synthetic short/small interfering RNAs (siRNA) can be utilized to trigger down-regulation of desired genes via transfecting into mammalian cells. Recently, utilization of polymeric carriers has been an attractive approach in drug delivery for medical applications. This review article describes the advantages of exploiting polymeric carriers for siRNA delivery, as bio-therapeutics. Here, we report the current developments, safety and delivery of bio-based siRNAs via polymeric carriers. Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been

🔖

Cite This Article

TÜZMEN, Ş., YALINCA, Z. (2022). ATTRACTIVE APPROACHES IN siRNA DELIVERY USING POLYMER BIO-BASED CARRIER SYSTEMS. Anadolu Üniversitesi Bilim ve Teknoloji Dergisi :C-Yaşam Bilimleri ve Biyoteknoloji, Cilt: 7 - Sayı: 1, 74–91. https://ajindex.com/articles/438569

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lee SH, Kang YY, Jang HE, Mok H. Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv Drug Deliv Rev 2016; 104: 78-92.
  2. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 12982-12987
  3. Czech MP, Aouadi M, Tesz GJ. RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 2011; 7: 473-484.
  4. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154-1158. Rondinone CM. Therapeutic potential of RNAi in metabolic diseases. Biotechniques 2006; 40: 31-36.
  5. Kumar P, Ban HS, Kim SS, Wu HQ, Pearson T, Greiner DL, Laouar A, Yao JH, Haridas V, Habiro K, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134: 577-586
  6. Li MJ, Li HT, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Oligonucleotide Therapeutics 2006; 1082: 172-179.
  7. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 2010; 28: 27-34.
  8. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA. Inhibition of hepatitis B virus in mice by RNA interference Nat Biotechnol 2003; 21: 639-644.
  9. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010; 28: 570-579.
  10. Guo W, Chen WB, Yu WD, Huang WL, Deng WG. Small interfering RNA-based molecular therapy of cancers. Chinese Journal of Cancer 2013; 32: 488-493.
  11. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 2012; 17:1044-1052.
  12. Saraswathy M, Gong SQ. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Materials Today 2014; 17: 298-306.
  13. Abbasi M, Lavasanifar A, Uludag H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 2013; 33: 33-53.
  14. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pa